Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256906 | 0.82 | TRPA1 (0.55) | AKT2AKT1ROCK2ROCK1BCL2L1 | |
| SCHEMBL30332929 | 0.82 | DPP4 (0.55) | AKT2AKT1ROCK2ROCK1PDK2 | |
| SCHEMBL28552255 | 0.79 | AKT2 (0.72) | AKT2AKT1ROCK2PDK2ADRA1D | |
| SCHEMBL3911134 | 0.76 | AKT2 (0.55) | AKT2AKT1ROCK2ROCK1PDK2 | |
| SCHEMBL30823569 | 0.75 | AKT2 (0.59) | AKT2AKT1ROCK2ROCK1PDK2 | |
| SCHEMBL30823568 | 0.75 | AKT2 (0.59) | AKT2AKT1ROCK2ROCK1PDK2 | |
| Hydrochloric Acid SCHEMBL23291032 | 0.74 | AKT2 (0.53) | AKT2AKT1ROCK2ROCK1PDK2 | |
| Hydrochloric Acid SCHEMBL30549522 | 0.74 | AKT2 (0.53) | AKT2AKT1ROCK2ROCK1PDK2 | |
| SCHEMBL117091 | 0.74 | PDCD1 (0.65) | PDK2BCL2L1PDCD1CD274 | |
| SCHEMBL30826353 | 0.74 | PDCD1 (0.65) | PDK2BCL2L1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | AKT2 1588/4885AKT1 2331/4885ROCK2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.